Remove incorrect beta-lactam (penicillin and cephalosporin) allergy labels to expand antibiotic options for patients with blood cancers.
Official title: Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention
Run by Abramson Cancer Center at Penn Medicine · NCT07133074 · Data updated 2026-11-12
This project tests a pharmacist-led process to remove incorrect penicillin or other beta-lactam allergy labels in hospitalized patients with blood cancers so they can receive preferred antibiotics and potentially have better outcomes.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3800 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | November 2028 |
| Study ends | November 2029 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07133074 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Hospitalized patients with a hematologic malignancy who have a documented history of a beta-lactam allergy and are admitted to the inpatient oncology service are the ideal candidates.
✕Probably not a fit
Patients with documented severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, or other exclusionary severe reactions are unlikely to benefit from delabeling.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The RENEW-IN intervention uses a pharmacist-led, multi-step algorithm to review and delabel reported beta-lactam (BL) allergies among patients hospitalized with hematologic malignancies. The process includes a detailed allergy history, RENEW-IN algorithm-guided selection for additional testing, electronic medical record review, and pharmacist-directed delabeling when appropriate. The trial measures changes in antibiotic prescribing and clinical outcomes, including BL use and infection-related complications. Patients with histories of severe cutaneous adverse reactions are excluded from the intervention.
Why it matters
Potential benefit: If successful, more patients with hematologic malignancies could safely receive beta-lactam antibiotics, potentially reducing infection-related complications and improving antibiotic effectiveness.
How similar studies have gone: Prior delabeling programs in general hospitalized populations have shown that roughly 90% of reported beta-lactam allergies are not true allergies and can be safely removed, but this approach has not been well studied in patients with hematologic malignancies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service * reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem) Exclusion Criteria: * patients with a history of severe cutaneous adverse reaction * patients with a history of Stevens-Johnson syndrome * patients with a history of toxic epidermal necrolysis * patients with a history of drug-induced exfoliative dermatitis * patients with a history of drug reaction with eosinophilia and systemic symptoms * patients with a history of acute generalized exanthematous pustulosis
Where it's running
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Ebbing Lautenbach, MD,MPH,MSCE
- Email: ebbing@pennmedicine.upenn.edu
- Phone: 215-898-6977
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy
This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.
-
CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant
This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.
-
Identifying biomarkers for CAR-T cell therapy in cancer patients
This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.
-
QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors
This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.
-
Short versus long maribavir treatment after allogeneic stem cell transplant
This trial tests whether a shorter or longer course of maribavir helps adults with refractory CMV infection after their first allogeneic stem cell transplant.
-
Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients
This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.